May 10, 2024 07:15 AM EDT
R&D

Macro­Gen­ics in­ves­ti­gates three pa­tient deaths in Phase 2 prostate can­cer drug tri­al

Ayisha Sharma

News Reporter

Macro­Gen­ics re­port­ed on Thurs­day af­ter­noon that three pa­tients died in a mid-stage tri­al of its an­ti­body-drug con­ju­gate for prostate can­cer. Two par­tic­i­pants died due to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times